COVID‐19 infection in solid organ transplant recipients: A single‐center experience with patients immediately after transplantation

Kolonko, Aureliusz; Dudzicz, Sylwia; Wiȩcek, Andrzej; Król, Robert

doi:10.1111/tid.13381

Cited by 27 publications

(28 citation statements)

References 12 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…To be included, the study must have reported clinical data on adult (A-CA) or pediatric (P-CA) cancer patients and SOT or HCT recipients with confirmed COVID-19. Our inclusion and exclusion criteria identified 64 SOT studies, 27 , 28 , 29 , 30 , 31 , 32 , 33 , 34 , 35 , 36 , 37 , 38 , 39 , 40 , 41 , 42 , 43 , 44 , 45 , 46 , 47 , 48 , 49 , 50 , 51 , 52 , 53 , 54 , 55 , 56 , 57 , 58 , 59 , 60 , 61 , 62 , 63 , 64 , 65 , 66 , 67 , 68 , 69 , 70 , 71 , 72 , 73 , 74 , 75 , 76 , 77 , 78 , 79 , 80 , 81 , 82 , 83 , 84 , 85 , 86 , 87 , 88 , 89 , 90 11 HCT studies,…”

Section: Methodsmentioning

confidence: 99%

COVID-19 in immunocompromised patients: A systematic review of cancer, hematopoietic cell and solid organ transplant patients

Belsky¹,

Tullius²,

Lamb³

et al. 2021

Journal of Infection

194

166

View full text Add to dashboard Cite

Background: The clinical impact of severe coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), in immunocompromised patients has not been systematically evaluated. Methods: We reviewed current literature reporting on COVID-19 in cancer (CA), hematopoietic cell (HCT), and solid organ transplant (SOT) patients and compared their clinical data and outcomes to the general population. For adult CA, HCT and SOT patients, an extensive search strategy retrieved all articles published until July 20, 2020 by combining the terms coronavirus, coronavirus infection, COVID-19 , and SARS-CoV-2 in PubMed, Cochrane, and Web of Science, and following the Preferred Reporting Items for Systematic Reviews and Meta-analysis guidelines. For the pediatric CA cohort, a global COVID-19 registry was used. For the general population cohort, a large meta-analysis was used to compare pooled prevalence estimates, and two large meta-analyses were utilized to serve as pooled comparators for hospitalized COVID-19 patients. Findings: Compared to the general population, adult CA and SOT patients with COVID-19 had higher comorbidities, greater levels of inflammatory markers at diagnosis, and higher rates of intensive care and hospital mortality. Pediatric CA patients and HCT patients with COVID-19 tended to have clinical presentations and outcomes similar to the general population. Interpretation: To our knowledge, this is the first systematic review evaluating COVID-19 phenotype and outcomes in immunocompromised patients and comparing them to the general population, which shows that hospital outcomes appear to be worse in adult CA and SOT patients, potentially due to their higher co-morbidity burden.

show abstract

Section: Methodsmentioning

confidence: 99%

COVID-19 in immunocompromised patients: A systematic review of cancer, hematopoietic cell and solid organ transplant patients

Belsky¹,

Tullius²,

Lamb³

et al. 2021

Journal of Infection

194

166

View full text Add to dashboard Cite

show abstract

“…Similarly, two of five recent liver transplant patients died after nosocomial infection diagnosed 9 and 36 days after transplantation 154 . Finally, among three kidney and one liver transplant recipients who contracted SARS‐CoV‐2 infection from an asymptomatic surgeon between 7 and 10 days after transplantation, one kidney recipient died after rapid clinical deterioration 155 . Peri‐transplant infection may also adversely affect graft outcome as suggested by a kidney transplant recipient with SARS‐CoV‐2 infection 24 days after transplantation who developed acute respiratory distress syndrome (ARDS) and AKI with induction of donor specific antibodies 101 .…”

Section: Considerations In the Peri‐transplant Periodmentioning

confidence: 97%

“…Based on the recognition of this higher risk, multiple transplant organizations have released recommendations regarding protecting newly transplanted patients from acquiring SARS‐CoV‐2 41,45 . Potential reasons for COVID‐19 in the peri‐transplant period include asymptomatic infection of the recipient at or around the time of transplantation, donor‐derived infections, community acquired infections by family members or social contacts, or nosocomial transmission by health care workers and/or patients in health care facilities 154‐156 . Screening of recipients and donors to exclude infection at the time of surgery seems mandatory as any type of surgery in a SARS‐CoV‐2 infected patient has been associated with significant postoperative pulmonary complications and high mortality.…”

Section: Considerations In the Peri‐transplant Periodmentioning

confidence: 99%

Impact of COVID-19 in solid organ transplant recipients

Danziger‐Isakov

Blumberg

Manuel

et al. 2021

American Journal of Transplantation

120

109

View full text Add to dashboard Cite

The coronavirus disease 2019 (COVID‐19) pandemic caused by the severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) exploded onto the world stage in early 2020. The impact on solid organ transplantation (SOT) has been profound affecting potential donors, candidates, and recipients. Importantly, decreased donations and the pressure of limited resources placed on health care by the pandemic also disrupted transplant systems. We address the impact of COVID‐19 on organ transplantation globally and review current understanding of the epidemiology, outcomes, diagnosis, and treatment of COVID‐19 in SOT recipients.

show abstract

“…All 34 included studies were published in 2020, of which 15 studies reported prevalence outcomes[18-32] and 31 studies reported death outcomes[7, 18, 21-24, 26-50]. There were 17 cohort studies[7, 19, 20, 23-25, 27, 31, 33, 35, 40, 42, 44-46, 49, 50], 12 case series[21, 30, 34, 36-39, 41, 43, 47, 48], and five cross-sectional studies[22, 26, 28, 29, 32]. The number of samples per study ranged from 3 to 7,154 with a total of 1,944 COVID-19 confirmed cases in 21,873 ESRD patients with RRT from 12 countries in four WHO regions which nine countries were high-income countries and three were upper-middle-income countries according to the World Bank classification[51].…”

Section: Resultsmentioning

confidence: 99%

Covid-19 in end-stage renal disease patients with renal replacement therapies: a systematic review and meta-analysis

Nopsopon

Kittrakulrat

Takkavatakarn

et al. 2021

Preprint

View full text Add to dashboard Cite

IntroductionThe novel coronavirus (COVID-19), caused by SARS-CoV-2, showed various prevalence and case-fatality rates (CFR) among patients with different pre-existing chronic conditions. End-stage renal disease (ESRD) patients with renal replacement therapy (RRT) might have a higher prevalence and CFR due to reduced immune function from uremia and kidney tropism of SARS-CoV-2, but there was no systematic study on the infection and mortality of the SARS-CoV-2 infection in ESRD patients who are on RRT.MethodsWe searched five electronic databases and performed a systematic review and meta-analysis up to June 30, 2020, to evaluate the prevalence and case fatality rate (CFR) of the COVID-19 infection among ESRD patients with RRT. The global COVID-19 data were retrieved from the international database on June 30, 2020, for estimating the prevalence and CFR of the general population as referencing points.ResultsOf 3,272 potential studies, 34 were eligible studies consisted of 1,944 COVID-19 confirmed cases in 21,873 ESRD patients with RRT from 12 countries in four WHO regions. The overall pooled prevalence in ESRD patients with RRT was 3.10% [95% confidence interval (CI) 1.25–5.72] which was higher than referencing 0.14% global average prevalence. The overall estimated CFR of COVID-19 in ESRD patients with RRT was 18.06% (95%CI 14.09– 22.32) which was higher than the global average at 4.98%.ConclusionsThis meta-analysis suggested high COVID-19 prevalence and CFR in ESRD patients with RRT. ESRD patients with RRT should have their specific protocol of COVID-19 prevention and treatment to mitigate excess cases and deaths.Author summaryChronic kidney disease (CKD) was associated with increasing severity and mortality of COVID-19. End-stage renal disease (ESRD) patients were at the terminal stage of CKD and had reduced immune function due to uremia. Additionally, ESRD patients with kidney transplantation had a diminished immune system from immunosuppressive agents. Kidneys might be the secondary target of SARS-CoV-2 after the respiratory tract regardless of the previous history of kidney disease, preferably the glomerulus, which was associated with the richness of some specific protein-coding genes in the kidney. The overall pooled prevalence in ESRD patients with renal replacement therapy was approximately 22 times of the referencing global average prevalence. The overall estimated case fatality rate of COVID-19 in ESRD patients with renal replacement therapy was approximately 3.6 times the global average. ESRD patients with renal replacement therapy had high COVID-19 prevalence and case fatality rate. We suggested that ESRD patients with renal replacement therapy should have their specific protocol of COVID-19 prevention and treatment to mitigate excess cases and deaths.

show abstract

COVID‐19 infection in solid organ transplant recipients: A single‐center experience with patients immediately after transplantation

Cited by 27 publications

References 12 publications

COVID-19 in immunocompromised patients: A systematic review of cancer, hematopoietic cell and solid organ transplant patients

COVID-19 in immunocompromised patients: A systematic review of cancer, hematopoietic cell and solid organ transplant patients

Impact of COVID-19 in solid organ transplant recipients

Covid-19 in end-stage renal disease patients with renal replacement therapies: a systematic review and meta-analysis

Contact Info

Product

Resources

About